Tyra Biosciences (TYRA) Cash from Financing Activities (2020 - 2026)
Tyra Biosciences (TYRA) posted Cash from Financing Activities of $160.4 million for Q1 2026, up 3324.79% on a QoQ basis from $4.7 million in Q4 2025, and up 7233.47% year-over-year from $2.2 million in Q1 2025.
Tyra Biosciences (TYRA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Tyra Biosciences' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $160.4 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 7233.47% year-over-year to $160.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $166.3 million (up 4048.07% YoY) and the FY2025 annual result came in at $8.1 million, down 95.99% from the prior year.
- Cash from Financing Activities was $160.4 million for Q1 2026 at Tyra Biosciences, up from $4.7 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $200.3 million in Q1 2024 and bottomed at $3000.0 in Q4 2022.
- A 5-year average of $21.9 million and a median of $467000.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 99.82% — and 2024, when it surged 53175.27%.
- Tyra Biosciences' Cash from Financing Activities stood at $3000.0 in 2022, then soared by 10700.0% to $324000.0 in 2023, then soared by 117.9% to $706000.0 in 2024, then surged by 563.31% to $4.7 million in 2025, then surged by 3324.79% to $160.4 million in 2026.
- Business Quant data shows TYRA's Cash from Financing Activities at $160.4 million in Q1 2026, $4.7 million in Q4 2025, and $647000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Tyra Biosciences | 1.90 Bn | 1.90 Bn | - | 160.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 160.38 Mn |
| Mar 31, 2026 | 160.38 Mn |
| Dec 31, 2025 | 4.68 Mn |
| Dec 31, 2025 | 4.68 Mn |
| Sep 30, 2025 | 647,000.00 |
| Sep 30, 2025 | 647,000.00 |
| Jun 30, 2025 | 583,000.00 |
| Jun 30, 2025 | 583,000.00 |
| Mar 31, 2025 | 2.19 Mn |
| Mar 31, 2025 | 2.19 Mn |
| Dec 31, 2024 | 706,000.00 |
| Dec 31, 2024 | 706,000.00 |
| Sep 30, 2024 | 743,000.00 |
| Sep 30, 2024 | 743,000.00 |
| Jun 30, 2024 | 373,000.00 |
| Jun 30, 2024 | 373,000.00 |
| Mar 31, 2024 | 200.32 Mn |
| Mar 31, 2024 | 200.32 Mn |
| Dec 31, 2023 | 324,000.00 |
| Dec 31, 2023 | 324,000.00 |